Compare Alcon AG (ALC) vs Axon Enterprise Inc (AXON) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Axon Enterprise Inc — how do they compare? Alcon AG trades at $66.87 (market cap $32.69B), while Axon Enterprise Inc trades at $600.43 (market cap $51.62B). The key difference: Axon Enterprise Inc is the larger of the two by market cap, and Alcon AG pays a 0.54% dividend while Axon Enterprise Inc pays none. Which is the better fit depends on your goals.
| ALC | AXON | |
|---|---|---|
Market Cap | $32.69B | $51.62B |
Sector | Health | Technology |
52-Week High | $92.22 | $870.97 |
52-Week Low | $62.02 | $345.94 |
Enterprise Value | $36.28B | $52.71B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Axon Enterprise (AXON) trades at $622.20, up 4.21% today, with strong technical momentum as it crosses above key moving averages. The stock shows robust revenue growth, reaching $2.78 billion in 2025, though valuation ratios like a P/E of 250.95 appear elevated. Recent news highlights FAA drone defense approvals and CEO focus on non-lethal public safety technology, driving positive sentiment.
Outlook remains positive with an 80.95% analyst buy rating and $661.50 consensus price target, but risks include high valuation sensitivity and mixed earnings beats. Growth in software services and international expansion offer upside, while cash flow volatility and competitive pressures require monitoring for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Axon Enterprise Inc
Axon develops technology and weapons for law enforcement and military use. Its ecosystem includes TASER devices, body cameras, and Evidence.com, a cloud-based platform for digital evidence management.
Read more on AXON →
